These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Lack of effect of cyclophosphamide on the immunogenicity of a melanoma antigen vaccine. Oratz R; Dugan M; Roses DF; Harris MN; Speyer JL; Hochster H; Weissman J; Henn M; Bystryn JC Cancer Res; 1991 Jul; 51(14):3643-7. PubMed ID: 2065322 [TBL] [Abstract][Full Text] [Related]
3. Preparation and characterization of a polyvalent human melanoma antigen vaccine. Bystryn JC; Jacobsen S; Harris M; Roses D; Speyer J; Levin M J Biol Response Mod; 1986 Jun; 5(3):211-24. PubMed ID: 3723138 [TBL] [Abstract][Full Text] [Related]
4. Effect of DETOX as an adjuvant for melanoma vaccine. Schultz N; Oratz R; Chen D; Zeleniuch-Jacquotte A; Abeles G; Bystryn JC Vaccine; 1995 Apr; 13(5):503-8. PubMed ID: 7639018 [TBL] [Abstract][Full Text] [Related]
5. Clinical activity of a polyvalent melanoma antigen vaccine. Bystryn JC Recent Results Cancer Res; 1995; 139():337-48. PubMed ID: 7597302 [TBL] [Abstract][Full Text] [Related]
7. Human high molecular weight-melanoma associated antigen mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: modulation of the immunogenicity in patients with malignant melanoma. Mittelman A; Chen GZ; Wong GY; Liu C; Hirai S; Ferrone S Clin Cancer Res; 1995 Jul; 1(7):705-13. PubMed ID: 9816036 [TBL] [Abstract][Full Text] [Related]
8. Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine. Hsueh EC; Gupta RK; Qi K; Morton DL J Clin Oncol; 1998 Sep; 16(9):2913-20. PubMed ID: 9738558 [TBL] [Abstract][Full Text] [Related]
9. Improved survival of patients with melanoma with an antibody response to immunization to a polyvalent melanoma vaccine. Miller K; Abeles G; Oratz R; Zeleniuch-Jacquotte A; Cui J; Roses DF; Harris MN; Bystryn JC Cancer; 1995 Jan; 75(2):495-502. PubMed ID: 7812920 [TBL] [Abstract][Full Text] [Related]
10. Enhanced humoral immune response correlates with improved disease-free and overall survival in American Joint Committee on Cancer stage II melanoma patients receiving adjuvant polyvalent vaccine. DiFronzo LA; Gupta RK; Essner R; Foshag LJ; O'Day SJ; Wanek LA; Stern SL; Morton DL J Clin Oncol; 2002 Aug; 20(15):3242-8. PubMed ID: 12149297 [TBL] [Abstract][Full Text] [Related]
11. Identification of immunogenic human melanoma antigens in a polyvalent melanoma vaccine. Bystryn JC; Henn M; Li J; Shroba S Cancer Res; 1992 Nov; 52(21):5948-53. PubMed ID: 1382848 [TBL] [Abstract][Full Text] [Related]
13. Humoral immune response to a therapeutic polyvalent cancer vaccine after complete resection of thick primary melanoma and sentinel lymphadenectomy. Chung MH; Gupta RK; Hsueh E; Essner R; Ye W; Yee R; Morton DL J Clin Oncol; 2003 Jan; 21(2):313-9. PubMed ID: 12525524 [TBL] [Abstract][Full Text] [Related]
14. Antigen-based immunotherapy of melanoma: Canvaxin therapeutic polyvalent cancer vaccine. Hsueh EC; Morton DL Semin Cancer Biol; 2003 Dec; 13(6):401-7. PubMed ID: 15001158 [TBL] [Abstract][Full Text] [Related]
15. Human high molecular weight melanoma-associated antigen mimicry by mouse antiidiotypic monoclonal antibody MK2-23. Characterization of the immunogenicity in syngeneic hosts. Chen ZJ; Yang H; Ferrone S J Immunol; 1991 Aug; 147(3):1082-90. PubMed ID: 1861071 [TBL] [Abstract][Full Text] [Related]
17. Immune response to postsurgical adjuvant active immunotherapy with Canvaxin polyvalent cancer vaccine: correlations with clinical course of patients with metastatic melanoma. Morton DL Dev Biol (Basel); 2004; 116():209-17; discussion 229-36. PubMed ID: 15603194 [TBL] [Abstract][Full Text] [Related]
18. Humoral immune response to intralymphatic immunotherapy for disseminated melanoma: correlation with clinical response. Ahn SS; Irie RF; Weisenburger TH; Jones PC; Juillard G; Roe DJ; Morton DL Surgery; 1982 Aug; 92(2):362-7. PubMed ID: 7101129 [TBL] [Abstract][Full Text] [Related]
19. Heterogeneous antibody response to polyvalent melanoma vaccines in syngeneic mice. Johnston D; Bystryn JC Cancer Immunol Immunother; 2005 Apr; 54(4):345-50. PubMed ID: 15692845 [TBL] [Abstract][Full Text] [Related]